Medicare Enrolled
Dr. Ricardo Parrondo, M.D.
Hematology & Oncology · Jacksonville, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Parrondo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Parrondo? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Parrondo
Dr. Ricardo Parrondo is a hematology & oncology in Jacksonville, FL, with 10 years in practice. Based on federal Medicare data, Dr. Parrondo performed 68,160 Medicare services across 2,192 unique beneficiaries.
Between the years covered by Open Payments, Dr. Parrondo received a total of $14,997 from 32 pharmaceutical and/or device companies across 102 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Parrondo is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 10 years in practice▲ Top 12% volume in FL$ $14,997 industry payments
Medicare Practice Summary
Medicare Utilization ↗68,160
Medicare services
Top 12% in FL for hematology & oncology
2,192
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~6,816 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 11,602 | $33 | $160 |
| Filgrastim injection (Nivestym) for white blood cells | 8,580 | $0 | $1 |
| Anti-nausea injection (fosaprepitant) | 6,300 | $0 | $1 |
| Nivolumab injection (Opdivo) | 5,880 | $22 | $104 |
| Iron infusion (Feraheme) | 5,610 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia | 5,405 | $2 | $11 |
| Daratumumab injection (Darzalex) | 4,680 | $38 | $189 |
| Injection, paclitaxel protein-bound particles, 1 mg | 4,100 | $10 | $51 |
| Denosumab injection (Prolia/Xgeva) | 3,000 | $19 | $91 |
| Paclitaxel chemotherapy injection | 2,946 | $0 | $2 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,520 | $21 | $190 |
| Dexamethasone injection (steroid) | 1,278 | $0 | $4 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,190 | $21 | $179 |
| Anti-nausea injection (ondansetron/Zofran) | 1,100 | $0 | $5 |
| Injection, atropine sulfate, 0.01 mg | 670 | $0 | $1 |
| Injection, bortezomib, 0.1 mg | 560 | $3 | $9 |
| Injection of additional new drug or substance into vein | 377 | $12 | $216 |
| Anti-nausea injection (Aloxi/palonosetron) | 330 | $1 | $8 |
| Administration of chemotherapy into vein, 1 hour or less | 239 | $101 | $869 |
| Injection, irinotecan, 20 mg | 188 | $2 | $23 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 180 | $79 | $502 |
| Hospital follow-up visit, high complexity | 175 | $94 | $452 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 170 | $3 | $38 |
| Office visit, established patient, complex (40-54 min) | 164 | $135 | $604 |
| Injection, carboplatin, 50 mg | 138 | $2 | $31 |
| Drug injection, under skin or into muscle | 128 | $11 | $102 |
| Injection, fluorouracil, 500 mg | 128 | $2 | $31 |
| Collection of blood sample from implanted device | 121 | $20 | $135 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 109 | $130 | $500 |
| Injection, magnesium sulfate, per 500 mg | 100 | $1 | $18 |
| Infusion, normal saline solution , 1000 cc | 96 | $2 | $82 |
| Administration of chemotherapy into vein, each additional hour | 93 | $22 | $212 |
| Infusion into a vein for hydration, each additional hour | 83 | $10 | $114 |
| Administration of additional new drug or substance into vein, 1 hour or less | 78 | $50 | $446 |
| Office visit, established patient (30-39 min) | 73 | $87 | $450 |
| Injection, diphenhydramine hcl, up to 50 mg | 69 | $1 | $37 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 66 | $26 | $200 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 62 | $22 | $233 |
| Injection, leucovorin calcium, per 50 mg | 57 | $3 | $30 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 56 | $56 | $352 |
| Hospital follow-up visit, moderate complexity | 52 | $62 | $314 |
| Infusion into a vein for hydration, 31-60 minutes | 47 | $25 | $345 |
| New patient office visit, complex (60-74 min) | 46 | $162 | $891 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 33 | $16 | $154 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 33 | $15 | $143 |
| Initial hospital admission, high complexity | 33 | $133 | $877 |
| Hospital discharge management, 30+ min | 32 | $92 | $487 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 31 | $48 | $426 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 30 | $1 | $80 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 29 | $28 | $105 |
| Injection of drug or substance into vein | 26 | $28 | $600 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 21 | $133 | $993 |
| Administration of additional new drug or substance into vein using push technique | 17 | $43 | $370 |
| Office visit, established patient (20-29 min) | 15 | $63 | $296 |
| Administration of chemotherapy into vein using push technique | 14 | $78 | $640 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
8.9% high complexity
89.7% medium
1.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,997
Total received (2018-2024)
Avg $2,142/year across 7 years
Top 31% in FL for hematology & oncology
32
Companies
102
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$8,884 (59.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,188 (34.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$925 (6.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,641
2023$3,228
2022$5,043
2021$212
2020$619
2019$3,297
2018$956
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GENZYME CORPORATION
$5,935
AstraZeneca Pharmaceuticals LP
$3,042
Janssen Biotech, Inc.
$859
Amgen Inc.
$840
Celgene Corporation
$575
Alexion Pharmaceuticals, Inc.
$497
Kite Pharma, Inc.
$357
Lilly USA, LLC
$341
Bayer HealthCare Pharmaceuticals Inc.
$338
GlaxoSmithKline, LLC.
$228
PFIZER INC.
$200
Astellas Pharma US Inc
$181
Seattle Genetics, Inc.
$178
Novartis Pharmaceuticals Corporation
$172
Genentech USA, Inc.
$164
Servier Pharmaceuticals LLC
$135
AbbVie Inc.
$127
EISAI INC.
$123
BeiGene USA, Inc.
$109
Daiichi Sankyo Inc.
$102
Janssen Scientific Affairs, LLC
$101
Seagen Inc.
$99
Merck Sharp & Dohme Corporation
$70
Adaptive Biotechnologies Corporation
$68
EUSA Pharma (US) LLC
$25
Puma Biotechnology, Inc.
$23
Kyowa Kirin, Inc.
$23
Astellas Pharma Global Development
$23
Jazz Pharmaceuticals Inc.
$18
Lexicon Pharmaceuticals, Inc.
$17
Foundation Medicine, Inc.
$14
Gilead Sciences, Inc.
$12
Top 3 companies account for 65.6% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · Abraxane · Aliqopa · BRUKINSA · CALQUENCE · CYRAMZA · DARZALEX · ELREXFIO · FOUNDATIONONE · Herceptin · IMBRUVICA · INREBIC · KEYTRUDA · Kyprolis · Lenvima · NERLYNX · Neulasta · Nplate · OJJAARA · ONCASPAR · POTELIGEO · RYDAPT · SANDOSTATIN LAR · SARCLISA · SOLIRIS · Sylvant · ULTOMIRIS · VENCLEXTA · VERZENIO · VYXEOS · Vitrakvi · XGEVA · XOSPATA · Xermelo · Yescarta · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (59%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $22 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
104
Per 100K population
10.3
County median income
$68,447
Nearest hospital
MAYO CLINIC
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Parrondo is a mixed practice specialist, with above-average Medicare volume (top 12% in FL), and consulting-driven industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Parrondo experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Parrondo performed 11,602 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Parrondo receive payments from pharmaceutical companies?
Yes. Dr. Parrondo received a total of $14,997 from 32 companies across 102 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Parrondo's costs compare to other hematology & oncologys in Jacksonville?
Dr. Parrondo's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Parrondo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Jacksonville
Browse hematology & oncologys in Jacksonville ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in FL
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in FL
Which FL hematology & oncologys receive the most from drug and device companies.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology